ARTICLE | Clinical News
EC approves BMS's Sprycel for pediatric ALL
February 15, 2019 7:43 PM UTC
The European Commission approved Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with chemotherapy to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval covers both tablet and powder for oral suspension formulations of Sprycel.
FDA expanded Sprycel's label last month to include pediatric Ph+ ALL patients...
BCIQ Company Profiles
BCIQ Target Profiles